GLPG1205   Click here for help

GtoPdb Ligand ID: 10171

Synonyms: compound 122 [WO2013092791A1] | GLPG-1205
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GLPG1205 is an investigational, orally bioavailable GPR84 antagonist that was being developed by Galapagos. The chemical structure is claimed as compound 122 in patent WO2013092791A1, for the treatment of inflammatory disorders [1]. Galapagos cut GLPG1205 (for idiopathic pulmonary fibrosis, IPF) from their development pipeline in a cost-cutting exercise in the first half of 2021. Their chitinase inhibitor, GLPG4617 (structure undisclosed), will be taken forward into a phase 2 study for IPF.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 62.58
Molecular weight 378.16
XLogP 4.67
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=c1nc(OCC2COCCO2)cc2n1CCc1c2ccc(c1)C#CC1CC1
Isomeric SMILES O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1c2ccc(c1)C#CC1CC1
InChI InChI=1S/C22H22N2O4/c25-22-23-21(28-14-18-13-26-9-10-27-18)12-20-19-6-5-16(4-3-15-1-2-15)11-17(19)7-8-24(20)22/h5-6,11-12,15,18H,1-2,7-10,13-14H2/t18-/m0/s1
InChI Key IRBAWVGZNJIROV-SFHVURJKSA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 2 evaluation of GLPG1205 efficacy in patients with ulcerative colitis has been completed (NCT02337608) and a Phase 2 trial in idiopathic pulmonary fibrosis (NCT03725852) is recruiting participants as of January 2019.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02337608 Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis Phase 2 Interventional Galapagos NV
NCT03725852 A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2 Interventional Galapagos NV